Filing Overview
Haleon plc filed a Form 6-K for August 2022, dated August 4, 2022, attaching a TR-1 notification of major holdings. The filing concerns a nominee-account transfer of Pfizer Inc.’s Haleon shares completed on August 3, 2022.
Business Context and Reporting Period
The filing is an ownership disclosure rather than an operating or financial-results report. It does not provide a reporting-period income statement, balance sheet, cash flow statement, or management discussion of business performance.
Ownership and Key Metrics
- Notifying shareholder: Pfizer Inc.
- Total voting rights held: 2,955,063,626, representing 32.0% of Haleon’s voting rights.
- Ordinary shares: 2,364,050,902 shares, representing 25.6% of voting rights.
- Restricted ADRs: 591,012,724, representing 6.4% of voting rights.
- Financial instruments: None reported; voting rights through financial instruments were 0.0%.
- Nominee transfer: Pfizer transferred its holding from Wealth Nominees Limited to N.Y. Nominees Limited.
- Prior position: Pfizer’s disclosed position remained 32.0%, with no change in the number of voting rights held.
Material Changes and Unusual Items
The change was administrative and resulted from a change of nominee shareholder. Pfizer stated that it did not cross any shareholding threshold and that the transfer did not change its beneficial ownership or voting position.
Financial Performance, Liquidity, and Outlook
The filing text does not provide clear values for revenue, profit, margins, cash flow, debt, liquidity, guidance, outlook, contingencies, or operating risks.
Facts Investors Should Verify
- Confirm that the nominee transfer was completed on August 3, 2022, without a change in Pfizer’s beneficial ownership.
- Verify the reported 32.0% voting-rights position and the underlying share and restricted-ADR counts.
- Review subsequent Haleon and Pfizer ownership disclosures for any later changes in Pfizer’s stake.
- Consult Haleon’s financial filings separately for operating results, leverage, liquidity, guidance, and risk factors, none of which are addressed in this filing.